Bitattun Takardu na BCMA CAR-T
Manyan bitattun takardu da ke tallafawa shirin maganin CAR-T na Hillgene wanda ke riƙe BCMA don cutar myeloma da raunin rigakafi.
Anti-BCMA CAR-T don Cutar da ke da alaƙa da IgG4
Nazarin asibiti da nazarin bayanai na salula guda ɗaya na maganin anti-BCMA CAR-T a cutar da ke da alaƙa da IgG4 — raunin rigakafi wanda yake da babban yuwuwar sake dawowa yayin rage maganin glucocorticoid. Yana nuna yuwuwar maganin da ke riƙe BCMA fiye da cututtukan fata. [Lancet Rheumatol 2025 · PubMed: 41109316]
BCMA CAR-T a Cikin Rashin Lafiyar Lupus Nephritis
Maganin sel na CAR T mai nufin BCMA yana daidaita warwatsar cututtuka a cikin marasa lafiya da ba sa amsa magani na lupus nephritis — aka buga a cikin Annals of the Rheumatic Diseases. Yana nuna ikon juyar da maganin sel mai nufin BCMA ga cututtukan koda na autoimmune. [Ann Rheum Dis 2025 · PubMed: 40681435]
In-Vivo BCMA CAR-T don Myeloma Mai dawowa/Wanda ba sa amsa
An buga a cikin The Lancet — maganin sel na CAR T na in-vivo mai nufin B-cell maturation antigen don myeloma mai yawa wanda ya dawo ko wanda ba sa amsa. Wani buga muhimmin aiki wanda ke nuna ci gaban maganin BCMA. [Lancet 2025 · PubMed: 40617243]
Mataki na I: Humanized BCMA Single-Domain CAR-T
Nazarin asibiti na mataki na I na humanized BCMA-single-domain antibodies da ke nufin CAR-T a cikin marasa lafiya da myeloma mai yawa wanda ya dawo ko wanda ba sa amsa. Yana nuna aminci da iyawar maganin sel na CAR-T mai nufin BCMA. [Cancer Biol Med 2025 · PubMed: 41117086]
Abubuwan da ba a sani ba na BCMA CAR-T a cikin Dabarun Myeloma
Nazarin gaggawa na baya-bayan nan na haɗari na BCMA CAR T-cell injection a cikin berayen B-NDG masu ƙwayar cutar myeloma mai yawa. Yana tallafawa bayyanar amincin maganin BCMA CAR-T kafin a yi amfani da shi a cikin mutane. [Front Immunol 2024 · PubMed: 39606226]
Single VHH-Directed BCMA CAR-T a cikin Myeloma
Sel na BCMA CAR-T masu nufin Single VHH sun haifar da warwatsar myeloma mai yawa wanda ya dawo/wanda ba sa amsa. An buga a cikin Leukemia (Nature) — yana nuna tasirin amfani da antibody mai tsaka-tsaki na single-domain don nufin BCMA. [Leukemia 2021 · PubMed: 34031533]